File photo
New Delhi, June 22
Regulatory experts on Tuesday reviewed and accepted Bharat Biotech’s phase-3 data that shows 77.8 per cent jab efficacy in a trial on 25,800 persons.
The study results are significant as they come on the eve of an important meeting Bharat Biotech representatives are expected to attend at the WHO tomorrow as a step towards Covaxin’s emergency use listing by the world body. Currently, only one India-made vaccine, Covishield, is mentioned in the WHO listing. Sources in the drug regulator’s office said Biotech had submitted vaccine efficacy data from phase-3 trials on the weekend and it was reviewed by subject experts today and accepted.
The regulator had in January this year granted emergency use approval to Covaxin in clinical trial mode with phase-3 data awaited. Bharat Biotech had earlier submitted its EUL application to the WHO. —TNS
Join Whatsapp Channel of The Tribune for latest updates.
Most Read In 24 Hours
Don't Miss
View All
Top News
Modi will continue to be PM even after being 75, says Amit Shah on Arvind Kejriwal's ‘age bar in BJP’ remark
There is nothing written in the BJP's constitution on any su...
BJP will not form government on June 4, says Arvind Kejriwal as he holds first roadshow during election campaign after release from jail
Says is fighting against dictatorship with all his power and...
Centre accepts IAS officer and BJP’s Bathinda candidate Parampal Kaur Sidhu’s resignation, asks Punjab for an NOC
Highly placed sources in the government have confirmed that ...
Eminent Punjabi poet Surjit Patar dies at 79
He was also the president of Punjabi Sahit Akademi and was a...
Punjab Police bust interstate drug smuggling gang
7 held with 70.42 lakh intoxicant pills, 725 kg tramadol pow...
